904763-27-5
904763-27-5 结构式
基本信息
ATN 161 TFA salt
ATN-161 TFA salt
ATN-161 Trifluoroacetate
ATN-161 trifluoroacetate salt
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-13535A | 904763-27-5 ATN-161 trifluoroacetate salt | 904763-27-5 | 2 mg | 800元 |
| 2024/04/30 | HY-13535A | 904763-27-5 ATN-161 trifluoroacetate salt | 904763-27-5 | 5mg | 1100元 |
| 2024/04/30 | HY-13535A | 904763-27-5 ATN-161 trifluoroacetate salt | 904763-27-5 | 10mg | 1600元 |
常见问题列表
Integrin α5β1
The combination of ATN-161 plus 5-FU significantly reduces tumor cell proliferation compared to control and single-agent therapy (p<0.01). In addition, combination therapy leads to a significant increase of apoptotic (TUNEL-positive) tumor cells (p<0.03), whereas single-agent therapy does not increase in TUNEL-positive tumor cells. ATN-161 treatment leads to a significant reduction in EC number (21% decrease) after a 48 hr incubation time compared to control (p<0.03). ATN-161 inhibites VEGF-induced migration and capillary tube formation in hCECs, but did not inhibit proliferation. ATN-161 decreases the number of cells migrating in response to VEGF in a dose-dependent manner starting at 100 nM (P<0.001 vs. VEGF group).
The preliminary experiments with α5β1-negative human colon cancer xenografts (HT29) show that treatment with ATN-161 significantly reduces tumor weight and vessel density. Injection of ATN-161 after laser photocoagulation inhibits choroidal neovascularization (CNV) leakage and neovascularization to an extent similar to AF564.